These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

242 related articles for article (PubMed ID: 35707391)

  • 21. Update on Lupus Nephritis: Core Curriculum 2020.
    Parikh SV; Almaani S; Brodsky S; Rovin BH
    Am J Kidney Dis; 2020 Aug; 76(2):265-281. PubMed ID: 32220510
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Measurement of interleukin-1 receptor antagonist in patients with systemic lupus erythematosus could predict renal manifestation of the disease.
    Brugos B; Kiss E; Dul C; Gubisch W; Szegedi G; Sipka S; Zeher M
    Hum Immunol; 2010 Sep; 71(9):874-7. PubMed ID: 20538031
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Efficacy of Belimumab for active lupus nephritis in a young Hispanic woman intolerant to standard treatment: a case report.
    Fontana F; Alfano G; Leonelli M; Cerami C; Ligabue G; Spinella A; Citriniti G; Manzini CU; Ferri C; Cappelli G
    BMC Nephrol; 2018 Oct; 19(1):276. PubMed ID: 30342482
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Severity of systemic lupus erythematosus with diffuse proliferative glomerulonephritis and the ineffectiveness of standard pulse intravenous cyclophosphamide therapy in Jamaican patients.
    Williams W; Bhagwandass A; Sargeant LA; Shah D
    Lupus; 2003; 12(8):640-5. PubMed ID: 12945726
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Choroidal thickness in lupus nephritis.
    Lee I; Marshall B; Ranganathan P; Eisen S; Rajagopal R; Kim AHJ; Li T
    Lupus; 2020 Feb; 29(2):205-209. PubMed ID: 31924146
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prevention of renal damage in murine lupus nephritis by CTLA-4Ig and cyclophosphamide.
    Cunnane G; Chan OT; Cassafer G; Brindis S; Kaufman E; Yen TS; Daikh DI
    Arthritis Rheum; 2004 May; 50(5):1539-48. PubMed ID: 15146424
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clinical effects of intermittent, intravenous cyclophosphamide in severe systemic lupus erythematosus.
    Martinelli R; Pereira LJ; Santos ES; Rocha H
    Nephron; 1996; 74(2):313-7. PubMed ID: 8893147
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Worse Renal Presentation and Prognosis in Initial-Onset Lupus Nephritis than Early-Onset Lupus Nephritis.
    Kwon OC; Park JH; Lee SW; Song JJ; Park YB; Park MC
    Yonsei Med J; 2020 Nov; 61(11):951-957. PubMed ID: 33107238
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [The roles of complement 1q and anti-C1q autoantibodies in pathogenesis of lupus nephritis].
    Zhang FC; Zhou B; Dong Y
    Zhonghua Yi Xue Za Zhi; 2005 Apr; 85(14):955-9. PubMed ID: 16061001
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pim-1 as a Therapeutic Target in Lupus Nephritis.
    Fu R; Xia Y; Li M; Mao R; Guo C; Zhou M; Tan H; Liu M; Wang S; Yang N; Zhao J
    Arthritis Rheumatol; 2019 Aug; 71(8):1308-1318. PubMed ID: 30791224
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Frequency of recurrent lupus nephritis among ninety-seven renal transplant patients during the cyclosporine era.
    Stone JH; Millward CL; Olson JL; Amend WJ; Criswell LA
    Arthritis Rheum; 1998 Apr; 41(4):678-86. PubMed ID: 9550477
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Outcomes following mycophenolate mofetil versus cyclophosphamide induction treatment for proliferative juvenile-onset lupus nephritis.
    Smith E; Al-Abadi E; Armon K; Bailey K; Ciurtin C; Davidson J; Gardner-Medwin J; Haslam K; Hawley D; Leahy A; Leone V; McErlane F; Mewar D; Modgil G; Moots R; Pilkington C; Ramanan A; Rangaraj S; Riley P; Sridhar A; Wilkinson N; Beresford MW; Hedrich CM
    Lupus; 2019 Apr; 28(5):613-620. PubMed ID: 30871425
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Predominance of CD8+ T lymphocytes among periglomerular infiltrating cells and link to the prognosis of class III and class IV lupus nephritis.
    Couzi L; Merville P; Deminière C; Moreau JF; Combe C; Pellegrin JL; Viallard JF; Blanco P
    Arthritis Rheum; 2007 Jul; 56(7):2362-70. PubMed ID: 17599764
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Renal vascular lesions in lupus nephritis.
    Descombes E; Droz D; Drouet L; Grünfeld JP; Lesavre P
    Medicine (Baltimore); 1997 Sep; 76(5):355-68. PubMed ID: 9352738
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Efficacy of mycophenolate mofetil in Japanese patients with systemic lupus erythematosus.
    Kawazoe M; Kaneko K; Yamada Z; Masuoka S; Mizutani S; Yamada S; Shikano K; Sato H; Kaburaki M; Muraoka S; Kawai S; Nanki T
    Clin Rheumatol; 2019 Jun; 38(6):1571-1578. PubMed ID: 30778862
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Deposition of the lectin pathway of complement in renal biopsies of lupus nephritis patients.
    Nisihara RM; Magrini F; Mocelin V; Messias-Reason IJ
    Hum Immunol; 2013 Aug; 74(8):907-10. PubMed ID: 23639552
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Short term administration of costimulatory blockade and cyclophosphamide induces remission of systemic lupus erythematosus nephritis in NZB/W F1 mice by a mechanism downstream of renal immune complex deposition.
    Schiffer L; Sinha J; Wang X; Huang W; von Gersdorff G; Schiffer M; Madaio MP; Davidson A
    J Immunol; 2003 Jul; 171(1):489-97. PubMed ID: 12817034
    [TBL] [Abstract][Full Text] [Related]  

  • 38. C-reactive protein, immunoglobulin G and complement co-localize in renal immune deposits of proliferative lupus nephritis.
    Sjöwall C; Olin AI; Skogh T; Wetterö J; Mörgelin M; Nived O; Sturfelt G; Bengtsson AA
    Autoimmunity; 2013 May; 46(3):205-14. PubMed ID: 23331132
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Dutch guidelines for diagnosis and therapy of proliferative lupus nephritis.
    van Tellingen A; Voskuyl AE; Vervloet MG; Bijl M; de Sévaux RG; Berger SP; Derksen RH; Berden JH;
    Neth J Med; 2012 May; 70(4):199-207. PubMed ID: 22641632
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Mycophenolate mofetil as maintenance therapy for childhood-onset systemic lupus erythematosus patients with severe lupus nephritis.
    Kizawa T; Nozawa T; Kikuchi M; Nagahama K; Okudela K; Miyamae T; Imagawa T; Nakamura T; Mori M; Yokota S; Tsutsumi H
    Mod Rheumatol; 2015 Mar; 25(2):210-4. PubMed ID: 25159157
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.